z-logo
open-access-imgOpen Access
Tumour cell‐intrinsic CTLA 4 regulates PD ‐L1 expression in non‐small cell lung cancer
Author(s) -
Zhang Huijun,
Dutta Pranabananda,
Liu Jinguo,
Sabri Nafiseh,
Song Yuanlin,
Li Willis X.,
Li Jinghong
Publication year - 2019
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13956
Subject(s) - cytotoxic t cell , cancer research , ctla 4 , biology , t cell , lung cancer , immune checkpoint , antibody , cell growth , carcinogenesis , cancer cell , cancer , immune system , immunotherapy , immunology , medicine , in vitro , biochemistry , genetics
Cytotoxic T lymphocyte antigen 4 ( CTLA 4) and programmed cell death protein 1 ( PD ‐1) are immune checkpoint proteins expressed in T cells. Although CTLA 4 expression was found in multiple tumours including non‐small cell lung cancer ( NSCLC ) tissues and cells, its function in tumour cells is unknown. Recently, PD ‐1 was found to be expressed in melanoma cells and to promote tumorigenesis. We found that CTLA 4 was expressed in a subset of NSCLC cell lines and in a subgroup of cancer cells within the lung cancer tissues. We further found that in NSCLC cells, anti‐ CTLA 4 antibody can induce PD ‐L1 expression, which is mediated by CTLA 4 and the EGFR pathway involving phosphorylation of MEK and ERK . In CTLA 4 knockout cells, EGFR knockout cells or in the presence of an EGFR tyrosine kinase inhibitor, anti‐ CTLA 4 antibody was not able to induce PD ‐L1 expression in NSCLC cells. Moreover, anti‐ CTLA 4 antibody promoted NSCLC cell proliferation in vitro and tumour growth in vivo in the absence of adaptive immunity. These results suggest that tumour cell‐intrinsic CTLA 4 can regulate PD ‐L1 expression and cell proliferation, and that anti‐ CTLA 4 antibody, by binding to the tumour cell‐intrinsic CTLA 4, may result in the activation of the EGFR pathway in cancer cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here